Note 10 - Shareholders' Equity |
3 Months Ended | |||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Mar. 31, 2025 | ||||||||||||||||||||||||||||||||||||
| Notes to Financial Statements | ||||||||||||||||||||||||||||||||||||
| Equity [Text Block] |
10. Shareholders’ Equity
Authorized capital shares
DiaMedica has authorized share capital of an unlimited number of voting common shares, and the shares do not have a stated par value. Common shareholders are entitled to receive dividends as declared by the Company, if any, and are entitled to one vote per share at the Company’s annual general meeting and any extraordinary or special general meeting.
Equity issued during the three months ended March 31, 2025
During the three months ended March 31, 2025, 3,805 common shares were issued upon the vesting and settlement of restricted stock units and 37,000 common shares were issued upon the exercise of stock options for gross proceeds of $94,000.
Equity issued during the three months ended March 31, 2024
During the three months ended March 31, 2024, 5,916 common shares were issued upon the vesting and settlement of restricted stock units.
Shares reserved
Common shares reserved for future issuance are as follows:
|
|||||||||||||||||||||||||||||||||||